1
|
Strus P, Borensztejn K, Szczepankiewicz AA, Lisiecki K, Czarnocki Z, Nieznanska H, Wojcik C, Bialy LP, Mlynarczuk-Bialy I. Novel podophyllotoxin and benzothiazole derivative induces transitional morphological and functional changes in HaCaT cells. Toxicol In Vitro 2021; 73:105144. [PMID: 33722735 DOI: 10.1016/j.tiv.2021.105144] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2021] [Revised: 02/24/2021] [Accepted: 03/09/2021] [Indexed: 10/21/2022]
Abstract
Podophyllotoxin (PPT) is an antimitotic drug used topically in the treatment of anogenital warts. Due to its toxicity it cannot be administered systemically as an anticancer agent. However, modified PPT derivatives such as etoposide and teniposide are used clinically as systemic agents. Thus, we invented novel PPT derivative KL3 that was synthesized by photocyclization. Earlier we have shown that KL3 has an anticancer effect in various cell lines. Here we compared the toxicity of KL3 vs PPT on non-cancerous normal human keratinocytes (HaCaT) and peripheral blood mononuclear cells (PBMC) showing that KL3 is less toxic than PPT to non-cancerous cells. At concentrations that neither induced cell death, nor affected cell cycle, KL3 in HaCaT cells evoked transient ultrastructural features of ER stress, swelling of mitochondria and elongation of cytoplasmic processes. Those changes partially reversed with prolonged incubation while features of autophagy were induced. PPT in equivalent concentrations induced HaCaT cell death by cell cycle arrest, intrinsic apoptosis and finally disintegration of cell membranes followed by secondary necrosis. In conclusion, we show that the KL3 derivative of PPT in contrast to PPT allows repair of normal keratinocytes and triggers mechanisms that restore non-tumor cell homeostasis.
Collapse
Affiliation(s)
- Piotr Strus
- Histology and Embryology Students Association at the Department for Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Poland
| | - Karol Borensztejn
- Histology and Embryology Students Association at the Department for Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Poland
| | - Andrzej Antoni Szczepankiewicz
- Laboratory of Electron Microscopy, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur St., 02-093 Warsaw, Poland
| | - Kamil Lisiecki
- Faculty of Chemistry, University of Warsaw, Pasteura 1, Warsaw 02-093, Poland
| | - Zbigniew Czarnocki
- Faculty of Chemistry, University of Warsaw, Pasteura 1, Warsaw 02-093, Poland
| | - Hanna Nieznanska
- Laboratory of Electron Microscopy, Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur St., 02-093 Warsaw, Poland
| | - Cezary Wojcik
- US Cardiovascular, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA
| | - Lukasz P Bialy
- Department for Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Poland
| | - Izabela Mlynarczuk-Bialy
- Department for Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Poland.
| |
Collapse
|
2
|
Smolinski MP, Bu Y, Clements J, Gelman IH, Hegab T, Cutler DL, Fang JWS, Fetterly G, Kwan R, Barnett A, Lau JYN, Hangauer DG. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). J Med Chem 2018; 61:4704-4719. [PMID: 29617135 DOI: 10.1021/acs.jmedchem.8b00164] [Citation(s) in RCA: 71] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal. Herein we describe the discovery of two such clinical candidates that inhibit the tyrosine kinase Src. Compound 1 is a phase 3 clinical trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing standard therapy. Compound 2 is a phase 1 clinical trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models. The discovery strategy for these compounds iteratively utilized molecular modeling, along with the synthesis and testing of increasingly elaborated proof of concept compounds, until the final clinical candidates were arrived at. This was followed with mechanism of action (MOA) studies that revealed tubulin polymerization inhibition as the second MOA.
Collapse
Affiliation(s)
- Michael P Smolinski
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - Yahao Bu
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - James Clements
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - Irwin H Gelman
- Department of Cancer Genetics & Genomics , Roswell Park Comprehensive Cancer Center , Elm and Carlton Streets , Buffalo , New York 14263 , United States
| | - Taher Hegab
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - David L Cutler
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - Jane W S Fang
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - Gerald Fetterly
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - Rudolf Kwan
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - Allen Barnett
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - Johnson Y N Lau
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| | - David G Hangauer
- Athenex Inc. , Conventus Building, 1001 Main Street, Suite 600 , Buffalo , New York 14203 , United States
| |
Collapse
|
3
|
Xiao Z, Morris-Natschke SL, Lee KH. Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates. Med Res Rev 2016; 36:32-91. [PMID: 26359649 PMCID: PMC4679534 DOI: 10.1002/med.21377] [Citation(s) in RCA: 118] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Natural products have made significant contribution to cancer chemotherapy over the past decades and remain an indispensable source of molecular and mechanistic diversity for anticancer drug discovery. More often than not, natural products may serve as leads for further drug development rather than as effective anticancer drugs by themselves. Generally, optimization of natural leads into anticancer drugs or drug candidates should not only address drug efficacy, but also improve absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles and chemical accessibility associated with the natural leads. Optimization strategies involve direct chemical manipulation of functional groups, structure-activity relationship directed optimization and pharmacophore-oriented molecular design based on the natural templates. Both fundamental medicinal chemistry principles (e.g., bioisosterism) and state-of-the-art computer-aided drug design techniques (e.g., structure-based design) can be applied to facilitate optimization efforts. In this review, the strategies to optimize natural leads to anticancer drugs or drug candidates are illustrated with examples and described according to their purposes. Furthermore, successful case studies on lead optimization of bioactive compounds performed in the Natural Products Research Laboratories at UNC are highlighted.
Collapse
Affiliation(s)
- Zhiyan Xiao
- Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China
- State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China
| | - Susan L. Morris-Natschke
- Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568, USA
| | - Kuo-Hsiung Lee
- Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568, USA
- Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan
| |
Collapse
|
4
|
Mahl A, Dincer Z, Heining P. The Potential of Minipigs in the Development of Anticancer Therapeutics: Species Comparison and Examples of Special Applications. Toxicol Pathol 2015; 44:391-7. [PMID: 26698323 DOI: 10.1177/0192623315619040] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Minipigs are increasingly being used as an alternative to dog or monkey in nonclinical safety testing of pharmaceuticals since they share similar anatomical and physiological characteristics to humans. Integrative assessment of pharmacodynamic and pharmacokinetic data sets of drug candidates fromin silico,in vitro, andin vivoinvestigations form the basis for selecting the most relevant nonrodent species for toxicology studies. Developing anticancer therapeutics represents a special challenge for species selection due to their effects on multiple organ systems. The toxicological profile of anticancer drugs can be associated with steep dose-response curves, especially due to dose-limiting toxicity on the alimentary, hematopoietic, and immune systems. Selection of an appropriate species for toxicology studies is of importance to avoid an inappropriately low (without benefit for the late-stage cancer patient) or high clinical starting dose (with a risk of unexpected adverse reactions). Although the minipig has been the preferred species to develop drugs applied topically, it is only rarely used in anticancer drug development compared to dog and monkey. In this context, we discuss the potential of minipigs in anticancer drug development with examples of programs for oral and dermal administration, intravascular application in drug-eluting stents, and local chemotherapy (chemoembolization).
Collapse
Affiliation(s)
- Andreas Mahl
- Novartis Institute for Biomedical Research, Preclinical Safety, Basel, Switzerland
| | - Zuhal Dincer
- Novartis Institute for Biomedical Research, Preclinical Safety, Basel, Switzerland
| | - Peter Heining
- Novartis Institute for Biomedical Research, Preclinical Safety, Basel, Switzerland
| |
Collapse
|
5
|
Mahl JA, Vogel BE, Court M, Kolopp M, Roman D, Nogués V. The minipig in dermatotoxicology: Methods and challenges. ACTA ACUST UNITED AC 2006; 57:341-5. [PMID: 16713702 DOI: 10.1016/j.etp.2006.03.004] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2006] [Accepted: 03/30/2006] [Indexed: 10/24/2022]
Abstract
In view of more morphological and physiological similarities between human and porcine skin than for other laboratory animal species, the minipig is a preferred model to evaluate the safety profile of dermally applied xenobiotics. Different methods of dermal administration and examples of non-invasive and invasive investigations during the in-life phase of the studies are described. Routine and special post-mortem examinations in dermal studies are presented to assess responses to the topical treatment of minipig skin. Challenges in dermal minipig studies are discussed with respect to animal welfare and husbandry, test formulations, application methods and different types of investigations. One of the most significant issues for dermal minipig studies is the extensive measures required to prevent cross-contamination of blood and tissue samples taken to monitor local and systemic exposure to the test item.
Collapse
Affiliation(s)
- Jörg Andreas Mahl
- Novartis Pharma AG, MUT-2881.128, Auhafenstr., CH-4132 Muttenz, Switzerland.
| | | | | | | | | | | |
Collapse
|